FGF-23 in children with CKD: a new player in the development of CKD-mineral and bone disorder

Ekaterini Siomou1, Constantinos J Stefanidis

  • 1Department of Child Health, Medical School, University of Ioannina, Ioannina, Greece. stefanid@hol.gr

Insights

Fibroblast growth factor-23 (FGF-23) is elevated early in children with chronic kidney disease (CKD), preceding other mineral and bone disorder (CKD-MBD) markers. Targeting this FGF-23 axis may prevent bone deformities and growth issues in pediatric CKD.

Area of Science:

  • Pediatric Nephrology
  • Endocrinology
  • Mineral and Bone Metabolism

Background:

  • Chronic kidney disease (CKD) in children causes mineral and bone disorders (CKD-MBD), leading to skeletal abnormalities and growth issues.
  • Traditional understanding implicates vitamin D, parathyroid hormone (PTH), calcium (Ca), and phosphate (P) disturbances in CKD-MBD pathogenesis.
  • Emerging research highlights fibroblast growth factor-23 (FGF-23) as a critical regulator of phosphate and vitamin D metabolism.

Purpose of the Study:

  • To investigate the role of FGF-23 in the early stages of CKD-MBD in pediatric populations.
  • To determine if elevated FGF-23 levels precede other biochemical markers of CKD-MBD.
  • To explore FGF-23 as a potential therapeutic target for managing CKD-MBD in children.

Main Methods:

  • Analysis of FGF-23 levels in pediatric CKD patients.
  • Correlation of FGF-23 levels with serum Ca, P, and PTH concentrations.
  • Review of existing literature on FGF-23's role in mineral metabolism.

Main Results:

  • Elevated FGF-23 levels were observed early in pediatric CKD, prior to detectable abnormalities in serum Ca, P, or PTH.
  • Increased FGF-23 induces phosphaturia and suppresses vitamin D synthesis, contributing to negative phosphate balance.
  • FGF-23 acts independently of PTH in regulating phosphate homeostasis.

Conclusions:

  • The bone-kidney-parathyroid axis, mediated by FGF-23, is a crucial factor in pediatric CKD-MBD.
  • Early detection and therapeutic targeting of FGF-23 may be vital for preventing skeletal complications in children with CKD.
  • FGF-23 represents a promising novel therapeutic target even in the initial phases of pediatric CKD.

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Roles of Electrolytes: Calcium and Phosphate01:27

Roles of Electrolytes: Calcium and Phosphate

Calcium and phosphate are essential electrolytes in the human body, with calcium being the most abundant mineral. Around 99% of the body's calcium is stored in the skeleton and teeth, forming a crystal lattice of mineral salts in combination with phosphates. Calcium plays crucial roles in various bodily functions such as blood clotting, neurotransmitter release, muscle tone maintenance, and nervous and muscle tissue excitability.
The calcium concentration in blood plasma is primarily regulated...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...